general transcription factor IIi pseudogene 14Genealiases: []
Q-omics provides the consensus-scored GTF2IP14 profile across patient tissues and cancer cell-line models. GTF2IP14 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, GTF2IP14 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, GTF2IP14 RNA expression shows 18,434 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, HNSC, and UVM as cancer lineages where GTF2IP14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF2IP14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF2IP14 survival associations across molecular data types. GTF2IP14 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF2IP14 RNA expression–survival associations across cancer types. High GTF2IP14 expression shows unfavorable associations in KICH, ACC, LGG and UVM, but favorable associations in UCS and HNSC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for GTF2IP14 RNA expression.
This table summarizes GTF2IP14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GTF2IP14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF2IP14 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, CHOL and READ. The HNSC box plot shows higher GTF2IP14 RNA expression in tumor versus normal tissue (log2 FC = +0.502, t-test p < 0.001).
This table shows molecular features associated with GTF2IP14 in patient tissues and cancer cell lines. In patient samples, GTF2IP14 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
